Last month, the ICH launched a draft on Drug Interaction Studies regulatory. The guideline includes the regulations of the European, American and Japanese medical agencies and covers both in vitro and clinical studies.
Drug Drug interaction studies in preclinical stage, reduces unexpected adverse events rate in clinical trails
Specialized manufacturer of in vitro kits to evaluate uptake transporters, OCT2 and MATE1.
Specialized manufacturer of in vitro kits indicated to evaluate pharmacological relevant efflux and uptake receptors for TDI assays.
In vitro systems based on HEK293 cells are a recommended technique to assess MATE1 transporter interactions during preclinical stages.
Among other things, the agency explains that DDIs are a critical factor in a drug’s overall benefit-risk profile.